Andrew P. Mazar
Equibles does not estimate personal net worth.
Get an email with a short summary when Actuate Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACTU alertsAbout Andrew P. Mazar
Andrew P. Mazar is recorded as COO at Actuate Therapeutics, Inc. (ACTU). The newest filing on record that lists Andrew P. Mazar as COO at Actuate Therapeutics, Inc. (ACTU) is dated April 6, 2026. Earlier roles on record: Board Member at Monopar Therapeutics (MNPR) until April 8, 2022. The proxy statement of Actuate Therapeutics, Inc. reports total compensation of $1,419,569 for Andrew P. Mazar in fiscal 2025, including a base salary of $450,000. Disclosed compensation is on record for 5 fiscal years. Actuate Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Actuate Therapeutics, Inc. includes Daniel M. Schmitt (CEO and Board Member), Paul Lytle (CFO), Aaron G.L. Fletcher (Board Member) and 7 others.
Affiliation history
-
Current
Start not stated–present
Last confirmed April 6, 2026
-
2014-01-01–2022-04-08
Company network
Leadership on record at Actuate Therapeutics, Inc.
- Daniel M. Schmitt CEO, Board Member
- Paul Lytle CFO
- Aaron G.L. Fletcher Board Member
- Amy Ronneberg Board Member
- Dr. Dan Zabrowski Board Member
- Dr. Roger Sawhney Board Member
- Jason Keyes Board Member
- Martin H. Huber, MD Board Member
- Roger Sawhney Board Member
- Todd Thomson Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Actuate Therapeutics, Inc. (ACTU) | Ph. D. Chief Operating Officer | $450,000 | $1,419,569 |
| 2024 | Actuate Therapeutics, Inc. (ACTU) | Ph. D. Chief Operating Officer | $450,000 | $675,000 |
| 2023 | Actuate Therapeutics, Inc. (ACTU) | Ph. D. Chief Operating Officer | $450,000 | $666,112 |
| 2020 | Monopar Therapeutics (MNPR) | Ph.D., Executive Vice President of Research & Development, Chief Scientific Officer and Director | $438,008 | $872,571 |
| 2019 | Monopar Therapeutics (MNPR) | Ph.D., Executive Vice President of Research & Development, Chief Scientific Officer and Director | $360,500 | $465,500 |
Recent activity
No call appearances or filed executive changes recorded yet.